Close

Biotinylated Human CD38 CAR Detection Reagent, Avi & His Tag (CARD-LX022)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Evaluating CAR expression is an essential step in the production of CAR-T cells. Creative biolabs provides several detection reagents which are uniquely suitable for evaluation of CAR expression. Biotinylated Human CD38 CAR Detection Reagent, Avi & His Tag is a special detection reagent which carries an Avi tag (Avitag™) at the C-terminus, followed by a polyhistidine tag, and is used to detect human CD38 CAR related to the study of B-cell Malignancies.

Specific Inquiry

  • Size:
  • Form:
  Add to Cart

Specifications

  • Target
  • CD38
  • Application
  • ELISA, FC
  • Purity
  • >90%
  • Endotoxin Level
  • Less than 1.0 EU per μg by the LAL method.
  • Storage
  • For long term storage, the product should be stored at lyophilized state at -32°C or lower.
    Please avoid repeated freeze-thaw cycles.
  • Application Notes
  • The optimal working dilutions should be determined by the end user.
  • Diseases
  • B-cell Malignancies
  • Molecular Characterization
  • It contains AA Val 43 - Ile 300 (Accession # NP_001766.2).
  • Conjugation
  • Biotin
  • Tag
  • Avi & His Tag
  • Size
  • 0.2 mg
  • Formulation
  • Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
  • Expression
  • Human HEK293 cells
  • Host Species
  • Human
  • Species Reactivity
  • Human
  • Form
  • Lyophilized

Target

  • Target Introduction
  • CD antigen CD38 is also known as ADP-ribosyl cyclase 1, which belongs to the ADP-ribosyl cyclase family. CD38 is expressed at high levels in pancreas, liver, kidney, brain, testis, ovary, placenta, malignant lymphoma and neuroblastoma. CD38 is a multifunctional ectoenzyme that catalyzes the synthesis and hydrolysis of cyclic ADP-ribose (cADPR) from NAD+ to ADP-ribose. These reaction products are essential for the regulation of intracellular Ca2+. The loss of CD38 function is associated with impaired immune responses, metabolic disturbances, and behavioral modifications. The CD38 protein is a marker of cell activation. It has been connected to HIV infection, leukemias, myelomas, solid tumors, type II diabetes mellitus and bone metabolism. CD38 has been used as a prognostic marker in leukemia.
  • Target Alternative Names
  • CD38 Molecule
  • Entrez Gene ID
  • 952

Customer Reviews and Q&As

There are currently no customer reviews or questions for Biotinylated Human CD38 CAR Detection Reagent, Avi & His Tag (CARD-LX022). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.